Carregant...
Fitxers
Tipus de document
ArticleVersió
Versió publicadaData de publicació
Llicència de publicació
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/225421
COVID-19 Pandemic Waves and 2024-2025 Winter Season in Relation to Angiotensin-Converting Enzyme Inhibitors, Angiotensin Receptor Blockers and Amantadine
Títol de la revista
Director/Tutor
ISSN de la revista
Títol del volum
Recurs relacionat
Resum
Early pandemic reports suggested improved outcomes inhypertensive COVID-19 patients treated with angiotensin-converting enzyme inhibitors(ACEI) or amantadine. This study evaluates their impact on disease progression.Methods: We analyzed 55,936 infected patients (March 2020–January 2025) and 2024hospital admissions within a free-access Barcelona metropolitan health consortium (n =192,651 as of March 2025). Hospitalizations, stratified by polypharmacy level (nT), werecompared via Chi-square tests. ICU admissions and length of stay in hospitalized patientswere assessed during the first month of key waves: initial A2a + B3a + B9 (n = 184, March2020), Delta (n = 158, July 2021), Omicron21K (n = 142, January 2022), and Omicron 24F (n= 8, January 2025). Results: Non-survivors were predominantly aged >60 years (96.3%) inthe first wave and >70 years (100%) in Delta/Omicron waves. Post-vaccination, mortalitydecreased in high-comorbidity groups, though hospitalizations/ICU admissions inyounger patients surpassed first-wave levels during Delta. Vaccinated ACEI/ARB-treatedpatients showed reduced hospitalizations across all polypharmacy groups: OR(noACEI/ACEI) = 1.21 (≥2 nT) to 4.26 (1 nT, p = 0.014); OR (noARB/ARB) = 1.24 (≥8 nT) to1.74 (2–7 nT, p = 0.01). No hospitalizations occurred in amantadine-treated patients aged<70. Conclusions: These findings suggest a potential protective effect of ACEI, ARBs, andamantadine against severe COVID-19 and support the safety and continuity of thesetreatments. Multicentric studies incorporating post-COVID syndrome data are needed tovalidate these observations if hospitalizations persist.
Matèries (anglès)
Citació
Citació
PUIGDELLÍVOL SÁNCHEZ, Anna, JUANES GONZÁLEZ, Marta, CALDERÓN VALDIVIEZO, Ana, LOSA PUIG, Helena, GONZÁLEZ SALVADOR, Marta, LEÓN PÉREZ, Marc, PUEYO ANTÓN, Luís, FRANCO ROMERO, Maite, LOZANO PAZ, Celia, CORTÉS BORRA, Albert, VALLS FOIX, Roger. COVID-19 Pandemic Waves and 2024-2025 Winter Season in Relation to Angiotensin-Converting Enzyme Inhibitors, Angiotensin Receptor Blockers and Amantadine. _Healthcare_. 2025. Vol. 13, núm. 11. [consulta: 27 de gener de 2026]. ISSN: 2227-9032. [Disponible a: https://hdl.handle.net/2445/225421]